X0306 4 2021-07-01 0 0001706431 Vir Biotechnology, Inc. VIR 0001207792 MORE ROBERT J C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 1 0 0 0 Common Stock 2021-07-01 4 S 0 4794 44.3065 D 64575 D Common Stock 2021-07-01 4 S 0 5986 45.2275 D 58589 D Common Stock 2021-07-01 4 S 0 890 46.2169 D 57699 D Common Stock 486111 I See footnote The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.81 to $44.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.91 to $46.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The shares are held by APNG 1. The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. However, the reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. /s/ Howard Horn, Attorney-in-Fact 2021-07-06